Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation

Bone Marrow Transplantation

Volumn 46, Issue 4, 2011, Pages 516-522

  Khabori, M A ^a   El Emary, M ^a   Xu, W ^b   Guyatt, G ^c   Galal, A ^a   Kuruvilla, J ^a   Lipton, J ^a   Messner, H ^a   Gupta, V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

allogeneic haematopoietic cell transplantation; AML; MDS; myeloablative; reduced intensity conditioning

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CALCIUM; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; FLUDARABINE; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; POSACONAZOLE; PREDNISONE; VITAMIN D; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLADDER DISEASE; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; COMORBIDITY; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OSTEOPOROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; WHOLE BODY RADIATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79953708226     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.164     Document Type: Article

References (33)

1. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for pa-tients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
2. Luger S, Ringden O, Perez WS, Zhang M-J, DiPersio JF, Sierra J et al. Similar outcomes using myeloablative versus reduced intensity and non-myeloablative allogeneic transplant preparative regimens for AML or MDS: from the Center for International Blood and Marrow Transplant Research. ASH Annu Meet Abstr 2008; 112: 348.
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Brandwein JM, Gupta V, Schuh AC, Schimmer AD, Yee K, Xu W et al. Predictors of response to reinduction chemother-apy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol 2008; 83: 54-58.
5. Appelbaum FR, Anderson J. Allogeneic bone marrow trans-plantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12(Suppl 1): S25-S29. (Pubitemid 28479000)
6. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
7. Sorror ML, Storer B, Storb RF. Validation of the hemato-poietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009; 15: 757-758.
8. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-1141.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
11. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4(Suppl 1): 42-93. (Pubitemid 16050339)
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
13. Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007; 13: 1469-1476. (Pubitemid 350091384)
14. Andrea B, Karen B, Doug R, Sergio G, Hillard L, Vincent H et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
15. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplan-tation for leukemia following a new busulfan and cyclopho-sphamide regimen. Blood 1987; 70: 1382-1388. (Pubitemid 18026142)
16. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
17. Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W et al. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning. Bone Marrow Transplant 2007; 40: 423-430. (Pubitemid 47288220)
18. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814-821. (Pubitemid 46902436)
19. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
20. Richard AN, Laura J, Pablo P, Jeannine SM, Barry S, John TS et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505.
21. Gupta V, Xu W, Sutherland R, Kamel-Reid S, Kuruvilla J, Loach D et al. Optimization of alemtuzumab dose for graft-versus-host disease prophylaxis for reduced intensity transplantation from unrelated donors for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009; 15: 124-125.
22. Martin PJ, Carpenter PA, Sanders JE, Flowers ME. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004; 79: 221-228. (Pubitemid 38620769)
23. Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10: 867-876. (Pubitemid 39625308)
24. Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004; 33: 397-404. (Pubitemid 38313088)
25. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
26. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568. (Pubitemid 19092391)
27. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodys-plastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010; 28: 405-411.
28. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439-3446.
29. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151. (Pubitemid 40175319)
30. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplas-tic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047-1055. (Pubitemid 44603937)
31. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor trans-plants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
32. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846. (Pubitemid 44154615)
33. Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010; 63: 64-74.